Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Zosano Pharma Corporation (ZSAN : NSDQ)
 
 • Company Description   
Zosano Pharma Corporation is a biopharmaceutical company. It is engaged in developing a transdermal micro needle patch system to deliver formulations of existing drugs through the skin for the treatment of a variety of indications. The Company's lead product candidates include Weekly ZP-PTH for severe osteoporosis; ZP-Glucagon for severe hypoglycemia and ZP-Triptan, for migraine. Zosano Pharma Corporation is headquartered in Fremont, California.

Number of Employees: 29

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.10 Daily Weekly Monthly
20 Day Moving Average: 238,084 shares
Shares Outstanding: 4.90 (millions)
Market Capitalization: $10.30 (millions)
Beta: 3.30
52 Week High: $37.45
52 Week Low: $1.33
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.41% 3.58%
12 Week -64.38% -59.96%
Year To Date -87.22% -84.39%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
34790 ARDENTECH COURT
-
FREMONT,CA 94555
USA
ph: 510-745-1200
fax: -
zsan-ir@zosanopharma.com http://www.zosanopharma.com
 
 • General Corporate Information   
Officers
Steven Lo - ChiefExecutiveOfficer
Christine Matthews - Chief Financial Officer
Steven A. Elms - Director
Linda S. Grais - Director
Kenneth R. Greathouse - Director

Peer Information
Zosano Pharma Corporation (CORR.)
Zosano Pharma Corporation (RSPI)
Zosano Pharma Corporation (CGXP)
Zosano Pharma Corporation (BGEN)
Zosano Pharma Corporation (GTBP)
Zosano Pharma Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 98979H301
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 4.90
Most Recent Split Date: 4.00 (0.03:1)
Beta: 3.30
Market Capitalization: $10.30 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.73
Price/Cash Flow: -
Price / Sales: 15.62
EPS Growth
vs. Year Ago Period: -181.00%
vs. Previous Quarter: -274.66%
Sales Growth
vs. Year Ago Period: -48.84%
vs. Previous Quarter: 51.72%
ROE
03/31/22 - -177.06
12/31/21 - -80.12
09/30/21 - -75.96
ROA
03/31/22 - -119.14
12/31/21 - -54.84
09/30/21 - -51.51
Current Ratio
03/31/22 - 1.61
12/31/21 - 1.04
09/30/21 - 1.56
Quick Ratio
03/31/22 - 1.61
12/31/21 - 1.04
09/30/21 - 1.56
Operating Margin
03/31/22 - -8,617.91
12/31/21 - -4,015.92
09/30/21 - -3,541.43
Net Margin
03/31/22 - -8,375.11
12/31/21 - -3,812.10
09/30/21 - -3,367.90
Pre-Tax Margin
03/31/22 - -8,375.11
12/31/21 - -3,812.10
09/30/21 - -3,367.90
Book Value
03/31/22 - 2.87
12/31/21 - 9.74
09/30/21 - 11.56
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©